Biogen Stock Rises After Earnings, Jump in Sales of Alzheimer’s Drug
Barron s Online · 1 week ago
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
- 213.51Add to watchlist-2.62 (-1.21%)At close:4:00 PM EDTThu. May 2, 2024212.70 -0.81 (-0.38%)After hrs:6:17 PM EDTThu. May 2, 2024Nasdaq Real Time Price (USD) · Market closed
- Open217.99High218.46Low213.14
- Mkt Cap31.09BP/E (TTM)26.69Div & YieldN/A & N/A
- Prev. Close216.1352 Wk. Low189.4452 Wk. High319.76
What analysts are sayingTop storiesRelated stocks
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan ...
Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases.
Breaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease, the first ...
Sep 29, 2023 · September 29, 2023 • News Release. TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States. FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA.
